Evidence map›Paper›PMID 41769453›Full record

ReviewCureus2026

The Atopic Dermatitis Patient Journey: From Awareness to Advanced Care.

Tripti Sharma, Ashwin Balasubramanian, Dhiraj Dhoot, Saiprasad Patil, Hanmant Barkate

Abstract readReview
In one paragraph

Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tripti SharmaDepartment of Global Medical Affairs, Glenmark Pharmaceuticals Limited, Mumbai, IND.
Ashwin BalasubramanianDepartment of Global Medical Affairs, Glenmark Pharmaceuticals Limited, Mumbai, IND.
Dhiraj DhootDepartment of Global Medical Affairs, Glenmark Pharmaceuticals Limited, Mumbai, IND.
Saiprasad PatilDepartment of Global Medical Affairs, Glenmark Pharmaceuticals Limited, Mumbai, IND.
Hanmant BarkateDepartment of Global Medical Affairs, Glenmark Pharmaceuticals Limited, Mumbai, IND.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that significantly impacts the physical, psychological, and social well-being of patients. While clinical guidelines offer structured treatment pathways, real-world patient experiences often differ from clinical expectations due to delayed diagnosis, misinformation, inconsistent care, and emotional distress. This narrative review explores the full spectrum of the AD patient journey, from pre-diagnosis awareness to maintenance therapy and advanced treatment access, highlighting the barriers patients face in navigating care. These include medical, psychological, financial, and systemic obstacles that impair treatment adherence and reduce quality of life (QoL). The importance of early recognition by primary care providers, timely referrals to dermatologists, and patient-centered communication is emphasized. Advancements in topical, systemic, and biologic therapies have transformed the therapeutic landscape; however, fears around steroid use, cost-related limitations, and inadequate care coordination persist. A shift toward proactive management, integration of teledermatology, and patient education programs can bridge the gap between clinical recommendations and real-world outcomes. Understanding the patient journey is essential for developing more inclusive and effective care models that improve long-term disease control and patient QoL.

Indexed as

atopic dermatitiscare pathwayexpectationspain pointspatient experiencepatient journeyquality of lifeteledermatologytreatment barriers

Identifiers

PMID41769453
PMCPMC12949480

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.